| abstract |
The doses and methods described herein are sufficient to reduce the desired pharmacokinetic (PK) and pharmacodynamic (PD) properties that inhibit alternative pathway complement activity, eg, the risk of complement breakthrough. It results in inhibition of at least 85% or more in vivo AP activity at a BID dose of about 120 mg to 200 mg, which results in plasma levels of at least about 65 ng / ml, which results in AP inhibition. In addition, the dosage forms described herein provide a significantly lower C max , which provides additional safety margins and superior dosing freedom. [Selection diagram] FIG. 13 |